Mount Sinai Health System
Search
Profile image of Nadejda Tsankova
  • Mount Sinai Doctors

Nadejda Tsankova, MD, PhD

Anatomic Pathology and Clinical Pathology

No Patient Experience Ratings

Education

MD, University of Texas Southwestern Medical School

PhD, University of Texas - Southwestern Medical Center

Residency, Pathology, Neuropathology

Columbia University Irving Medical Center

Fellowship, Neuropathology

Columbia University Irving Medical Center

Certifications

American Board of Pathology

Awards

2022

Permanent member, NIH Clinical Neuroimmunology and Brain Tumor Study Section

NIH

2021

Rubenstein Award

AANP

2016

Faculty Idea Prize Winner, Mount Sinai Innovations

Mount Sinai Hospital

2016

Friedman Brain Institute Research Scholar

Mount Sinai Hospital

2013

Clinical Trials Office Research Pilot Award

Irving Institute

2008

Stembridge Award for Excellence in Pathology

University of Texas

2000

Medical Scientist Training Program Fellowship

1998

Howard Hughes Fellowship for summer research

1998

Presidential Endowed Scholarship

Research

The main research focus of the Tsankova laboratory is to understand the cellular and molecular mechanisms driving aberrant glial proliferation and migration in two debilitating CNS disorders – glioblastoma and epilepsy, focusing on the role of epigenetics and the transcriptional machinery in maintaining these dysfunctional glial phenotypes.  Our primary model is human pathological tissue obtained from neurosurgical resections and perpetuated in the form of spheroids or mouse xenografts. Our lab has developed unique techniques for the acute isolation of viable glial/neural populations in such tissues, using novel markers for cell quiescence and activation.  The lab is actively characterizing, both functionally and molecularly, novel populations of cancer stem cells and pathologically remodeled glial progenitors, in order to obtain deeper mechanistic insight into the role of glial proliferation and migration in CNS disease as well as to discover superior new targets for treatment of glioblastoma and drug-resistant epilepsy. We are using various techniques, such as ChIP-seq, ATAC-seq, single cell and bulk RNA-seq, CRISPR/Cas9 genome editing, tissue culture, and orthotopic xenotransplantation, and collaborate with several labs who share our passion for neuro-epigenetics.

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Industry Relationships